2024

Impact

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">Pfizer has <a aria-label="reaffirmed (opens in a new tab)" href="https://www.businesswire.com/news/home/20241217352989/en/Pfizer-Provides-Full-Year-2025-Guidance-and-Reaffirms-Full-Year-2024-Guidance" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">reaffirmed</a> its guidance for the full year 2024 and provided new projections for 2025. The pharmaceutical giant has set its revenue expectations for 2025 between $61.0 billion and $64.0 billion, with adjusted diluted <a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="noopener noreferrer nofollow" class="deco-link">earnings per share (EPS)</a> anticipated to range from $2.80 to $3.00. <br><br>The company has achieved significant cost savings of $4.0 billion through 2024 and expects to save an additional $500 million in 2025. Pfizer’s Manufacturing Optimization Program will deliver further cost efficiencies by late 2025, reflecting the company’s commitment to financial discipline and operational efficiency.</p>
<p>Pfizer’s 2025 revenue guidance suggests a stable performance in COVID-19 product sales compared to 2024, excluding a one-time $1.2 billion revenue from Paxlovid. The company anticipates operational revenue growth to remain flat or increase by up to 5% from the 2024 baseline. <br><br>Adjusted Selling, Informational, and Administrative (SI&amp;A) expenses for 2025 are projected to be between $13.3 billion and $14.3 billion, while Research and Development (R&amp;D) expenses are expected to range from $10.7 billion to $11.7 billion.</p>
<p>The guidance also considers a negative impact of $1 billion due to the Inflation Reduction Act (IRA) Part D redesign. Despite these challenges, Pfizer expects year-over-year growth in adjusted diluted EPS between 10% and 18% from the 2024 midpoint, even considering a $0.6 billion impact from generic and biosimilar competition.</p>
<h3 id="likely-impact-of-guidance-on-pfizer-s-stock-performance">Likely Impact of Guidance on Pfizer’s Stock Performance</h3>
<p>Pfizer’s reaffirmation of its financial guidance and strategic initiatives is likely to influence its stock performance positively. The company’s focus on cost management and operational growth signals potential for delivering significant shareholder value. Investors may find confidence in Pfizer’s robust pipeline and strategic initiatives, which are expected to support future growth. <br><br>The absence of share repurchases for 2024 and 2025, with EPS guidance based on 5.74 billion shares outstanding, indicates a clear strategy to maintain financial stability and growth.</p>
<p>Pfizer’s stock has experienced minor fluctuations, with a recent decrease of 0.39% to $25.48. The stock opened at $25.59 and reached a day low of $25.2218, with a high of $25.74. Over the past year, the stock has ranged from a low of $24.48 to a high of $31.54. <br><br>Despite the recent dip, analysts maintain varied ratings, with Morgan Stanley holding an Equal-Weight position, Wells Fargo rating it as Overweight, and B of A Securities upgrading it from Neutral to Buy. Goldman Sachs projects 2025 EPS in the mid-to-high $2 range, with revenues forecasted at $64.9 billion, slightly above consensus estimates.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="analysts-recommend-a-buy-for-pfizer-s-stock">Analysts Recommend a “Buy” for Pfizer’s stock</h3>
<p>Pfizer’s market capitalization is $143.09 billion, with a <a href="https://tokenist.com/investing/what-is-dividend-investing/" class="deco-link" rel="noopener noreferrer nofollow">dividend yield</a> of 6.81%. The stock’s forward P/E ratio is 8.77, indicating potential for growth relative to its <a href="https://tokenist.com/investing/p-e-ratio/" rel="noopener noreferrer nofollow" class="deco-link">trailing P/E ratio</a> of 33.67. Key metrics such as the debt-to-equity ratio of 73.408 and a book value of $16.288 highlight the company’s financial health. <br><br>Analysts recommend a “Buy” with a mean target price of $31.99, suggesting a potential upside from current levels. Investors will closely watch Pfizer’s strategic execution and market dynamics, including the impact of the IRA Part D redesign and the sales performance of key products like Paxlovid and Vyndaqel.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/pfizer-targets-up-to-64b-revenue-in-2025-amid-strategic-cost-savings/">Pfizer Targets Up to $64B Revenue in 2025 Amid Strategic Cost Savings</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Pfizer Targets Up to $64B Revenue in 2025 Amid Strategic Cost Savings

Table of Contents

Tokenist

Other articles published on Dec 17, 2024

The memecoin market cap surpasses $140 billion

Circle and Binance Form Strategic Partnership to Drive Global Adoption of USDC

Ethereum Spot ETFs See $2.32B Inflows as Grayscale ETHE Dominates with $5.87B Assets

Bitcoin Forecast: Bitfinex Predict Price Surge to $200K by Mid-2025 on the Back of Milestones

Ripple RLUSD to Launch Today Across Major Exchanges, Paving the Way for Cross-Border Payments

Namada proposal seeks approval for NAM airdrop to Coin Center donors

Join our free newsletter for daily crypto updates!